372 related articles for article (PubMed ID: 24798416)
1. Statin use is associated with a decreased risk of Barrett's esophagus.
Nguyen T; Khalaf N; Ramsey D; El-Serag HB
Gastroenterology; 2014 Aug; 147(2):314-23. PubMed ID: 24798416
[TBL] [Abstract][Full Text] [Related]
2. Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett's esophagus: a nested case-control study.
Nguyen T; Duan Z; Naik AD; Kramer JR; El-Serag HB
Gastroenterology; 2015 Nov; 149(6):1392-8. PubMed ID: 26208896
[TBL] [Abstract][Full Text] [Related]
3. Reduced Risk of Barrett's Esophagus in Statin Users: Case-Control Study and Meta-Analysis.
Beales IL; Dearman L; Vardi I; Loke Y
Dig Dis Sci; 2016 Jan; 61(1):238-46. PubMed ID: 26386857
[TBL] [Abstract][Full Text] [Related]
4. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ;
Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200
[TBL] [Abstract][Full Text] [Related]
5. Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans.
Lin D; Kramer JR; Ramsey D; Alsarraj A; Verstovsek G; Rugge M; Parente P; Graham DY; El-Serag HB
Am J Gastroenterol; 2013 Oct; 108(10):1576-83. PubMed ID: 23857477
[TBL] [Abstract][Full Text] [Related]
6. Does this patient have Barrett's esophagus? The utility of predicting Barrett's esophagus at the index endoscopy.
Eloubeidi MA; Provenzale D
Am J Gastroenterol; 1999 Apr; 94(4):937-43. PubMed ID: 10201460
[TBL] [Abstract][Full Text] [Related]
7. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans.
Tan MC; El-Serag HB; Yu X; Thrift AP
Aliment Pharmacol Ther; 2018 Aug; 48(4):469-477. PubMed ID: 29956826
[TBL] [Abstract][Full Text] [Related]
8. Barrett's esophagus and medications that relax the lower esophageal sphincter.
Corley DA; Levin TR; Habel LA; Buffler PA
Am J Gastroenterol; 2006 May; 101(5):937-44. PubMed ID: 16573773
[TBL] [Abstract][Full Text] [Related]
9. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus.
Nguyen DM; Richardson P; El-Serag HB
Gastroenterology; 2010 Jun; 138(7):2260-6. PubMed ID: 20188100
[TBL] [Abstract][Full Text] [Related]
10. Risk Profiles for Barrett's Esophagus Differ between New and Prevalent, and Long- and Short-Segment Cases.
Tan MC; Murrey-Ittmann J; Nguyen T; Ketwaroo GA; El-Serag HB; Thrift AP
PLoS One; 2016; 11(12):e0169250. PubMed ID: 28036381
[TBL] [Abstract][Full Text] [Related]
11. Abdominal obesity and body mass index as risk factors for Barrett's esophagus.
Corley DA; Kubo A; Levin TR; Block G; Habel L; Zhao W; Leighton P; Quesenberry C; Rumore GJ; Buffler PA
Gastroenterology; 2007 Jul; 133(1):34-41; quiz 311. PubMed ID: 17631128
[TBL] [Abstract][Full Text] [Related]
12. Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma.
Beales IL; Vardi I; Dearman L
Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):917-23. PubMed ID: 22569083
[TBL] [Abstract][Full Text] [Related]
13. Interactions among smoking, obesity, and symptoms of acid reflux in Barrett's esophagus.
Smith KJ; O'Brien SM; Smithers BM; Gotley DC; Webb PM; Green AC; Whiteman DC
Cancer Epidemiol Biomarkers Prev; 2005 Nov; 14(11 Pt 1):2481-6. PubMed ID: 16284367
[TBL] [Abstract][Full Text] [Related]
14. Medical Prevention of Barrett's Esophagus: Effects of Statins, Aspirin, Non-aspirin NSAIDs, Calcium, and Multivitamins.
Goldberg A; Gerkin RD; Young M
Dig Dis Sci; 2015 Jul; 60(7):2058-62. PubMed ID: 25680872
[TBL] [Abstract][Full Text] [Related]
15. No association between hOGG1, XRCC1, and XPD polymorphisms and risk of reflux esophagitis, Barrett's esophagus, or esophageal adenocarcinoma: results from the factors influencing the Barrett's adenocarcinoma relationship case-control study.
Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):736-9. PubMed ID: 18349297
[TBL] [Abstract][Full Text] [Related]
16. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.
Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
Am J Gastroenterol; 1997 Nov; 92(11):2012-6. PubMed ID: 9362182
[TBL] [Abstract][Full Text] [Related]
17. Association between the body mass index and the risk of Barrett's esophagus in Japan.
Shinkai H; Iijima K; Koike T; Abe Y; Dairaku N; Inomata Y; Kayaba S; Ishiyama F; Oikawa T; Ohyauchi M; Ito H; Asonuma S; Hoshi T; Kato K; Ohara S; Shimosegawa T
Digestion; 2014; 90(1):1-9. PubMed ID: 25074386
[TBL] [Abstract][Full Text] [Related]
18. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus.
Eisen GM; Sandler RS; Murray S; Gottfried M
Am J Gastroenterol; 1997 Jan; 92(1):27-31. PubMed ID: 8995932
[TBL] [Abstract][Full Text] [Related]
19. Barrett's surveillance identifies patients with early esophageal adenocarcinoma.
Wong T; Tian J; Nagar AB
Am J Med; 2010 May; 123(5):462-7. PubMed ID: 20399324
[TBL] [Abstract][Full Text] [Related]
20. Metabolic syndrome and the risk of Barrett's oesophagus in white males.
Thrift AP; Hilal J; El-Serag HB
Aliment Pharmacol Ther; 2015 Jun; 41(11):1182-9. PubMed ID: 25801197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
